SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis
Authors:
Open Access
- 11 January 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1280547
Abstract
Coronary heart disease is a narrowing or obstruction of the vascular cavity caused by atherosclerosis of the coronary arteries, which leads to myocardial ischemia and hypoxia. At present, percutaneous coronary intervention (PCI) is an effective treatment for coronary atherosclerotic heart disease. Restenosis is the main limiting factor of the long-term success of PCI, and it is also a difficult problem in the field of intervention. Sodium-glucose cotransporter 2 (SGLT2) inhibitor is a new oral glucose-lowering agent used in the treatment of diabetes in recent years. Recent studies have shown that SGLT2 inhibitors can effectively improve the prognosis of patients after PCI and reduce the occurrence of restenosis. This review provides an overview of the clinical studies and mechanisms of SGLT2 inhibitors in the prevention of restenosis, providing a new option for improving the clinical prognosis of patients after PCI.Keywords
Funding Information
- National Natural Science Foundation of China (82300440)
This publication has 172 references indexed in Scilit:
- Insulin resistance and inflammation markers in myocardial infarctionJournal of Inflammation Research, 2013
- Smooth Muscle–Selective Inhibition of Nuclear Factor‐κB Attenuates Smooth Muscle Phenotypic Switching and Neointima Formation Following Vascular InjuryJournal of the American Heart Association, 2013
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part IEuropean Heart Journal, 2013
- Cellular Dysfunction in Diabetes as Maladaptive Response to Mitochondrial Oxidative StressExperimental Diabetes Research, 2012
- MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodellingCardiovascular Research, 2011
- Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family membersDiabetes Therapy, 2010
- Molecular Insights and Therapeutic Targets for Diabetic Endothelial DysfunctionCirculation, 2009
- The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitusCardiovascular Diabetology, 2009
- Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetesMicrovascular Research, 2008
- Apelin is a novel angiogenic factor in retinal endothelial cellsBiochemical and Biophysical Research Communications, 2004